“…In these studies, simple achiral catalysts were employed to provide racemic products; however, benzothiadiazine‐1‐oxides possess a chiral sulfur center, whose stereochemistry can affect their biological activity and physiological properties [9] . Although enantioselective C−H functionalization reactions [10] of sulfoximines via desymmetrization [11a,b,d,e, 12] or kinetic resolution [11c,d,f, 13] have been developed using Rh III catalysts with a chiral Cp x ligand [14] by Li [11a] and Cramer [11b,c] or using the combination of a Ru II catalyst and a chiral carboxylic acid co‐catalyst [15–20] by Shi [11d] and our group, [11e] or using a Pd II /MPAA catalyst by Gandon and Sahoo, [11f] only enantioselective C−C bond formation has been reported, while reports on enantioselective C−N bond formation remain elusive. In addition, the enantioselective C−H functionalization of sulfoximines using Earth‐abundant first‐row transition metal catalysts has not yet been reported.…”